肝炎后肝硬化患者肝癌发生的保护因素与危险因素研究
|
摘要
目的
通过回顾性病例对照研究以及PS(Propensity score)研究方法,探讨多种因素在病毒性肝炎后肝化门静脉高压症患者HCC发生过程中的作用以及脾切除是否抑制了肝癌的发生进程。
方法
收集第四军医大学西京医院病案统计室检索2002年1月～2008年12月之间出院诊断为病毒性肝炎后(HBV /HCV)肝硬化门脉高压的病例2300余例,收集所有病例的一般资料,临床及实验室检查数据,影象学检查结果,以及在治疗过程中的脾切除手术史。采用病例对照,按年龄、性别两个指标进行1:1配对,根据研究对象是否合并HCC将其分为合并HCC组(组1),未合并HCC组(组2),采用SPSS17.0进行单因素分析及多因素logistic回归分析。
此外,针对该结果采用PS法进行分析,以年龄、性别及肝炎类别作为需均衡的协变量进行均衡并以是否有脾切除手术史分组,以1:2配对最终得到954例病例,其中合并脾切除手术史患者(组1),未合并脾切除手术史患者,对两组数据进行统计分析。
结果
描述性统计结果显示,两组的ALB、AST、TP、ALP、GGT等差异有统计学意义(P<0.05),而PLT、ALT、TBIL等在两组间差异无统计学意义(P>0.05)。将单因素分析有意义的研究因素纳入多因素logistic回归方程得知,AST、ALP、GGT异常升高增加了肝癌发生的危险性,而行脾切除和门奇断流术明显降低了肝癌发生的危险性,仅为无手术患者肝癌发生危险性的57.1%(OR:0.571,95%CI: 0.394～0.825)。
通过PS方法也证实了这一结论,既往有脾切除手术史组患者肝癌发生的比例(18.6%),明显低于没有脾切除手术史组患者肝癌发生的比例(31.8%),且有无发生肝癌在两组之间差异有统计学意义(P<0.05)。
结论
AST、ALP和GGT的异常升高则提示其肝癌发生的危险性增加。脾切除和门奇断流术可显著降低肝炎后肝硬化伴门脉高压、脾功能亢进患者肝癌发生的危险性,
Object :
To investigate the effects of hypersplenism and splenectomy procedure on hepatocarcinogenesis for posthepatitic cirrhosis patients and evaluate whether splenectomy can restrain the progress of hepatocarcinogenesis by retrospective case-control study and propensity score methods.
Methods:
2300 patients with posthepatitis cirrhosis and hypersplenism in our hospital from January 2002 to December 2008 were included in this study. The patients paired by 1:1 according to gender and age were divided into two groups: these cases with hepatocellular carcinoma(HCC) in group1 , without HCC in group2. Clinical datas and history of splenectomy plus porta-azygous disconection were collected. Univariate and multivariate logistic regression analysis of the impact of splenectomy on hepatocarcinogenesis were performed by SPSS17.0
Otherwise, PS matching techniques were used to adjust the age, gender and hepatitis variety, then take statistical analysis with the patients which were paired by 1:2 according to history of splenectomy into two groups: these cases with history of splenectomy plus porta-azygous disconection in group1, without history of splenectomy plus porta-azygous disconection in group2.
Results:
Statistical results showed that between group 1 and 2 there was statistically significant difference in albumin (ALB)、aspartate aminotransferase (AST)、total protein (TP)、alkaline phosphatase (ALP)、γ-glutamyltransferase (GGT) (P<0.05), but no statistically significant difference in alanine transarninase (ALT)、total bilirubin (TBIL), and platelet count(PLT)(P>0.05). Single-variable and multivariate analysis revealed that the patients with abnomal of AST,ALP, GGT increased the risk of hepatocarcinogenesis. Compareing patients with and without history of splenectomy plus porta-azygous disconection ,this procedure significant decrease the risk of hepatocarcinogenesis(Odds ratio,OR:0.571,Confidence interval of 95%: 0.394～0.825). And the result was justified by PS matching method, there was statistically significant difference in the proportion of hepatocarcinogenesis in the patients( P<0.05) , the patients with history of splenectomy plus porta-azygous disconnection was lower than the patients whithout history of splenectomy plus porta-azygous disconnection.
Conclusions:
This study showed that the abnomal of AST, ALP and GGT increased the risk of hepatic carcinoma in patients of posthepatitis cirrhosis with portal hypertension and hypersplenism. Splenectomy with porta-azygous disconection decreased the risk of hepatocarcinogenesis in these patients.
通过回顾性病例对照研究以及PS(Propensity score)研究方法,探讨多种因素在病毒性肝炎后肝化门静脉高压症患者HCC发生过程中的作用以及脾切除是否抑制了肝癌的发生进程。
方法
收集第四军医大学西京医院病案统计室检索2002年1月～2008年12月之间出院诊断为病毒性肝炎后(HBV /HCV)肝硬化门脉高压的病例2300余例,收集所有病例的一般资料,临床及实验室检查数据,影象学检查结果,以及在治疗过程中的脾切除手术史。采用病例对照,按年龄、性别两个指标进行1:1配对,根据研究对象是否合并HCC将其分为合并HCC组(组1),未合并HCC组(组2),采用SPSS17.0进行单因素分析及多因素logistic回归分析。
此外,针对该结果采用PS法进行分析,以年龄、性别及肝炎类别作为需均衡的协变量进行均衡并以是否有脾切除手术史分组,以1:2配对最终得到954例病例,其中合并脾切除手术史患者(组1),未合并脾切除手术史患者,对两组数据进行统计分析。
结果
描述性统计结果显示,两组的ALB、AST、TP、ALP、GGT等差异有统计学意义(P<0.05),而PLT、ALT、TBIL等在两组间差异无统计学意义(P>0.05)。将单因素分析有意义的研究因素纳入多因素logistic回归方程得知,AST、ALP、GGT异常升高增加了肝癌发生的危险性,而行脾切除和门奇断流术明显降低了肝癌发生的危险性,仅为无手术患者肝癌发生危险性的57.1%(OR:0.571,95%CI: 0.394～0.825)。
通过PS方法也证实了这一结论,既往有脾切除手术史组患者肝癌发生的比例(18.6%),明显低于没有脾切除手术史组患者肝癌发生的比例(31.8%),且有无发生肝癌在两组之间差异有统计学意义(P<0.05)。
结论
AST、ALP和GGT的异常升高则提示其肝癌发生的危险性增加。脾切除和门奇断流术可显著降低肝炎后肝硬化伴门脉高压、脾功能亢进患者肝癌发生的危险性,
Object :
To investigate the effects of hypersplenism and splenectomy procedure on hepatocarcinogenesis for posthepatitic cirrhosis patients and evaluate whether splenectomy can restrain the progress of hepatocarcinogenesis by retrospective case-control study and propensity score methods.
Methods:
2300 patients with posthepatitis cirrhosis and hypersplenism in our hospital from January 2002 to December 2008 were included in this study. The patients paired by 1:1 according to gender and age were divided into two groups: these cases with hepatocellular carcinoma(HCC) in group1 , without HCC in group2. Clinical datas and history of splenectomy plus porta-azygous disconection were collected. Univariate and multivariate logistic regression analysis of the impact of splenectomy on hepatocarcinogenesis were performed by SPSS17.0
Otherwise, PS matching techniques were used to adjust the age, gender and hepatitis variety, then take statistical analysis with the patients which were paired by 1:2 according to history of splenectomy into two groups: these cases with history of splenectomy plus porta-azygous disconection in group1, without history of splenectomy plus porta-azygous disconection in group2.
Results:
Statistical results showed that between group 1 and 2 there was statistically significant difference in albumin (ALB)、aspartate aminotransferase (AST)、total protein (TP)、alkaline phosphatase (ALP)、γ-glutamyltransferase (GGT) (P<0.05), but no statistically significant difference in alanine transarninase (ALT)、total bilirubin (TBIL), and platelet count(PLT)(P>0.05). Single-variable and multivariate analysis revealed that the patients with abnomal of AST,ALP, GGT increased the risk of hepatocarcinogenesis. Compareing patients with and without history of splenectomy plus porta-azygous disconection ,this procedure significant decrease the risk of hepatocarcinogenesis(Odds ratio,OR:0.571,Confidence interval of 95%: 0.394～0.825). And the result was justified by PS matching method, there was statistically significant difference in the proportion of hepatocarcinogenesis in the patients( P<0.05) , the patients with history of splenectomy plus porta-azygous disconnection was lower than the patients whithout history of splenectomy plus porta-azygous disconnection.
Conclusions:
This study showed that the abnomal of AST, ALP and GGT increased the risk of hepatic carcinoma in patients of posthepatitis cirrhosis with portal hypertension and hypersplenism. Splenectomy with porta-azygous disconection decreased the risk of hepatocarcinogenesis in these patients.
引文
[1] Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127:S5–S16.
[2] Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet2003;362:1907–1917.
[3] CDC. Geographic Distribution of Chronic HBV Infection. Hepatitis B Slide Set (Internet) 2002.
[4]梁晓峰,陈园生,王晓军,贺雄,陈丽娟,王骏,林长缨,白呼群,严俊,崔钢,于竞进.中国3岁以上人群乙型肝炎血清流行病学研究.中华流行病学杂志2005,9;26(9).
[5] Velázquez RF, Rodríguez M, Navascués CA, Linares A, Pérez R, Sotorríos NG, Martínez I, Rodrigo L. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003 Mar;37(3):520-7.
[6] Peck-Radosavljevic M.Hypersplenism. Eur J Gastroenterol Hepatol 2001 Apr;13(4):317-23.
[7] Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533–543.
[8] McGlynn KA, Tsao L, Hsing AW, Devesa SS & Fraumeni Jr. JF. International trends and patterns of primary liver cancer. Int J Cancer 2001; 94: 290–296.
[9] Man-Fung Yuen1, Yasuhito Tanaka2, Daniel Yee-Tak Fong3,et al. Independent risk factors and predictive score for the development ofhepatocellular carcinoma in chronic hepatitis B. Journal of Hepatology. 2009;50:80–88.
[10] J.L. Rodri′guez-Di′az*, V. Rosas-Camargo*, O. Vega-Vegaz , et al. Clinical and Pathological Factors Associat-ed the Development of Hepatocellular Carcinoma in Patients with Hepatitis Virus-related Cirrhosis: A long-term Follow-up Study. Clinical Oncology 2007;19: 197-203.
[11] Parkin DM, Whelan SL, Ferlay J, Teppo L & Thomas DB (eds.) Cancer Incidence in Five Continents IARC Scientific Publications No. 155, vol. VIII. Lyon: IARC Press, 2002.
[12] Katherine A. McGlynn* PhD. Epidemiology and natural history of hepatocellular carcinoma. Best Practice & Research Clinical Gastroenterology.Vol. 19, No. 1, pp. 3–23, 2005
[13] J.L. Rodri′guez-Di′az*, V. Rosas-Camargo*, O. Vega-Vegaz , et al. Clinical and Pathological Factors Associat-ed the Development of Hepatocellular Carcinoma in Patients with Hepatitis Virus-related Cirrhosis: A long-term Follow-up Study. Clinical Oncology 2007;19: 197-203.
[14] Tanaka K, Hirohata T, Takeshita S, Hirohata I, Koga S,Sugimachi K, et al. Hepatitis B virus, cigarette smoking and alcohol consumption in the development of hepatocellular carcinoma: a case-control study in Kukuoka, Japan. Int J Cancer
[15] Jorge A. Marrero*, Robert J. Fontana, Sherry Fu.etal. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. Journal of Hepatology.2005;42: 218–224.
[16] Donato F, Tagger A, Chiesa R, Ribero ML, Tomasoni V, Fasola M, etal.Hepatitis B and C virus infection, alcohol drinking and hepatocellular carcinoma: a case-control study in Italy. Hepatology.1997;26:579–584.
[17]范宗华,褚天新,范宗林,等.饮酒与消化道肿瘤死亡关系的队列研究[J].现代预防医学,1996,23(1):20-22.
[18] Agudo A, Ahrens W, Benhamou E, Benhamou S, Boffetta P,Darby SC, et al. Lung cancer and cigarette smoking in women: a multicenter case-control study in Europe. Int J Cancer 2000;88:820–827.
[19] Oshima A, Tsukuma H, Hiyama T, Fujimoto I, Yamano H & Tanaka M. Follow-up study of HBsAg-positive blood donors with special reference to effect of drinking and smoking on development of liver cancer. Int J Cancer 1984; 34: 775–779.
[20] Yu MW, Hsu FC & Sheen IS. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 1997; 145: 1039–1047.
[21] Aizawa Y, Shibamoto Y, Takagi I, Zeniya M & Toda G. Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. Cancer 2000; 89: 53–59.
[22] Donato F, Tagger A, Gelatti U et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002; 155: 323–331.
[23] McCoy GD, Hecht SS, Katayama S &Wynder EL. Differential effect of chronic ethanol consumption on the carcinogenicity of N-nitroso-pyrrolidine and N0-nitrosonornicotine in male Syrian golden hamsters. Cancer Res 1981; 41: 2849–2854.
[24] Seitz HK, Poschl G & Simanowski UA. Alcohol and cancer. Recent Development Alcoholism 1998; 14: 67–95.
[25] Yu SY, Zhu YJ, LiWG et al. A preliminary report on the intervention trials of primary liver cancer in high risk populations with nutritional supplementation of selenium in China. Biol Trace Elem Res 1991; 29: 289–294.
[26] Yu MW, Horng IS, Hsu KH, Chiang YC, Liaw YF & Chen CJ. Plasma selenium levels and risk of hepatocellular carcinoma among men with chronic hepatitis infection. Am J Epidemiol 1999; 150: 367–374.
[27] Hsing AW, GwoW, Chen J, Stone BJ, BlotWJ & Fraumeni Jr. JF. Correlates of liver cancer mortality in China. Int J Epidemiol 1991; 20: 54–59.
[28] Klaunig JE. Chemopreventive effects of green tea components on hepatic carcinogenesis. Prev Med 1992;21: 510–519.
[29] Evans AA, Chen G, Ross EA et al. Eight-year follow-up of the 90,000-person Haimen City Cohort: Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol Biomarkers Prev 2002; 11: 369–376.
[30] Mu LN, Zhou XF, Ding BG et al. A case-control study on drinking green tea and decreasing risk of cancers in the alimentary canal among cigarette smokers and alcohol drinkers. Zhonghua Liu Xing Bing Xue Za Zhi 2003; 24: 192–195.
[31] World Cancer Research Fund, American Institute for cancer research, Liver In Food, Nutrition and the Prevention of Cancer: A Global Perspective. Washington, DC: American Institute for Cancer Research; 1997 pp. 202–214.
[32] Lopez-Garcia E, van Dam RM, Li TY, Rodriguez-Artalejo F, Hu FB. The relationship of coffee consumption with mortality. Ann Intern Med2008;148:904-914.
[33] Ruhl CE, Everhart JE. Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2005;128:24-32.
[34] Klatsky AL, Morton C, Udaltsova N, Friedman GD. Coffee, cirrhosis, and transaminase enzymes. Arch Intern Med 2006;166:1190-1195.
[35] Tanaka K, Tokunaga S, Kono S, et al. Coffee consumption and decreased serum gamma-glutamyltransferase and aminotransferase activities among male alcohol drinkers. Int J Epidemiol 1998;27:438-443.
[36] Casiglia E, Spolaore P, Ginocchio G, Ambrosio GB. Unexpected effects of coffee consumption on liver enzymes. Eur J Epidemiol 1993;9:293-297.
[37] Kono S, Shinchi K, Imanishi K, Todoroki I, Hatsuse K. Coffee and serumgamma-glutamyltransferase: a study of self-defense officials in Japan. Am J Epidemiol 1994;139:723-727.
[38] Honjo S, Kono S, Coleman MP, et al. Coffee drinking and serum gammaglutamyltransferase:an extended study of Self-Defense Officials of Japan. Ann Epidemiol 1999;9:325-331.
[39] Honjo S, Kono S, Coleman MP, et al. Coffee consumption and serum aminotransferases in middle-aged Japanese men. J Clin Epidemiol 2001;54:823-829.
[40] Corrao G, Zambon A, Bagnardi V, D’Amicis A, Klatsky A. Coffee, caffeine,and the risk of liver cirrhosis. Ann Epidemiol 2001;11:458-465.
[41] Tverdal A, Skurtveit S. Coffee intake and mortality from liver cirrhosis.Ann Epidemiol 2003;13:419-423.
[42] Gelatti U, Covolo L, Franceschini M, Pirali F, Tagger A, Ribero ML, et al.Coffee consumption reduces the risk of hepatocellularcarcinomaindependently of its aetiology: a case-control study. J Hepatol 2005;42:528-534.
[43] Inoue M, Yoshimi I, Sobue T, Tsugane S. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. J Natl Cancer Inst 2005;97:293-300.
[44] Shimazu T, Tsubono Y, Kuriyama S, et al. Coffee consumption and the risk of primary liver cancer: pooled analysis of two prospective studies in Japan. Int J Cancer 2005;116:150-154
[45] Gallus S, Bertuzzi M, Tavani A, Bosetti C, Negri E, La Vecchia C, et al.Does coffee protect against hepatocellular carcinoma? Br J Cancer 2002; 87:956-959.
[46] Bravi F, Bosetti C, Tavani A, et al. Coffee drinking and hepatocellular carcinoma risk: a metaanalysis.Hepatology 2007;46:430-435.
[47] Larsson SC, Wolk A. Coffee consumption and risk of liver cancer: a meta analysis.Gastroenterology 2007;132:1740-1745.
[48] Apurva A. Modi, Jordan J. Feld, Yoon Park. Increased Caffeine Consumption Is Associated with Reduced Hepatic Fibrosis. Hepatology 2010;51:201-209.
[49] McGlynn KA, Tsao L, Hsing AW, Devesa SS & Fraumeni Jr. JF. International trends and patterns of primary liver cancer. Int J Cancer 2001; 94: 290–296.
[50] Tagger A, Donato F, Ribero ML et al. Case–control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: the role of HCV genotypes and the synergism with hepatitis B virus and alcohol. Brescia HCC Study. Int J Cancer 1999; 81: 695–699.
[51] Linet MS, Gridley G, Nyren O et al. Primary liver cancer, othermalignancies, and mortality risks following porphyria: a cohort study in Denmark and Sweden. Am J Epidemiol 1999; 149: 1010–1015.
[52] Gordeuk VR, McLaren CE, Macphail AP, Deichsel G & Bothwell TH. Associations of iron overload in Africa with hepatocellular carcinoma and tuberculosis: Strachan’s 1929 thesis revisited. Blood 1996; 87:3470–3476.
[53] Nagasue, N., Kohno, H., 1992. Hepatocellular carcinoma and sex hormones. HPB-Surg. 6, 1–6.
[54] Collaborative Milts Project Team. Oral contraceptives and liver cancer. Contraception 1997; 56: 275–284.
[55] Hannaford PC, Kay CR, Vessey MP, Painter R & Mant J. Combined oral contraceptives and liver disease.Contraception 1997; 55: 145–151.
[56] WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Depot-medroxyprogesterone acetate (DMPA) and risk of liver cancer. Int J Cancer 1991; 49: 182–185.
[57] . Soe KL, Soe M & Gluud CN. Liver pathology associated with the use of anabolic–androgenic steroids. Liver 1992; 12: 73–79.
[58] IARC Monographs, Overall Evaluations Of Carcinogenicity: An Updating of IARC Monographs, vol. 1–42, supplement 7. Lyon: IARC Press; 1987.
[59] De Maria N, Manno M & Villa E. Sex hormones and liver cancer. Mol Cell Endocrinol 2002; 193: 59–63.
[60] Yu MW& Chen CJ. Elevated serum testosterone levels and risk of hepatocellular carcinoma. Cancer Res 1993; 53: 790–79.
[61] Yuan JM, Ross RK, Stanczyk FZ et al. A cohort study of serum testosterone and hepatocellular carcinoma in Shanghai, China. Int J Cancer 1995; 63: 491–493.
[62] La Vecchia C, Negri E, Franceschi S & D’avanzo B. Reproductive factorsand the risk of hepatocellular carcinoma in women. Int J Cancer 1992; 52: 351–354.
[63] HsingAW, McLaughlin JK, Hoover RN, Co Chien HT, BlotWJ & Fraumeni Jr. JF. Parity and primary liver cancer among young women. J Natl Cancer Inst 1992; 84: 1118–1119.
[64] Cole P, MacMahon B & Brown JB. Oestrogen profiles of parous and nulliparous women. Lancet 1976; 2:596–599.
[65] Mucci LA, Kuper HE, Tamimi R, Lagiou P, Spanos E & Trichopoulos D. Age at menarche and age at menopause in relation to hepatocellular carcinoma in women. BJOG 2001; 108: 291–294.
[66] Von Kaick, G., Wesch, H., 1984. Follow-up study. In: Von Kaick, G., Muth, A., Kaul, A. (Eds.), The German Thorotrast Study. Commission of the Europe on Communities, Luxembourg, pp. 190–211.
[67] Mori T, Fukutomi K, Kato Y et al. 1998 results of the first series of follow-up studies on Japanese Thorotrast patients and their relationships to an autopsy series. Radiat Res 1999; 152: S72–S80.
[68] Wong RH, Chen PC, Du CL, Wang JD & Cheng TJ. An increased standardized mortality ratio for liver cancer among polyvinyl chloride workers in Taiwan. Occup Environ Med 2002; 59: 405–409.
[69] Chiou H-Y, Hsueh Y-M, Liaw K-F et al. Incidence of internal cancers and ingested inorganic arsenic: a seven-year follow-up study in Taiwan. Cancer Res 1995; 55: 1296–1300.
[70] Lewis DR, Southwick JW, Ouellet-Hellstrom R, Rench J & Calderon RL. Drinking water arsenic in Utah: a cohort mortality study. Environ Health Perspect 1999; 107: 359–365.
[71]苏德隆.饮水中蓝绿藻毒素与肝癌的研究〔J〕.医学研究通讯, 2001,30(6): 19- 20.
[72] Park H, Namikoshi M, Brittain SM, Carmichael WW, Murphy T. Microcystin-LR, a new microcystin isoplated from waterbloom in a Canadian prairie lake. Toxicon. 2001 Jun;39(6):855-62.
[73]胡志坚,陈华,庞春艳,林其英.微囊藻毒素对肝细胞凋亡相关基因表达的影响〔J〕.中华预防医学杂志, 2007, 41(1): 13- 16.
[74]周珏平,沈建国,童建.微囊藻毒素LR对小鼠肝脏和淋巴细胞的损伤效应〔J〕.环境与职业医学, 2003, 20(1): 41- 42.
[75] Zegura B, Sedmak B, Filipic M.Microeystin LR induces oxidative DNA damage in human hepatoma cell line HepG2. Toxicon. 2003 Jan;41(1):41-8
[76] Shun-Zang, Y., 1990. Drinking water and primary liver cancer. In: Tang, Z.Y., Wo, M.C., Yia, S.S. (Eds.), Primary Liver Cancer. Springer-Verlaag, Berlin, pp. 30–37.
[77] Colombo, M., 1992. Hepatocellular carcinoma. J. Hepatol. 15, 225–236.
[78] Garner RC, Miller EC & Miller JA. Liver microsomal metabolism of aflatoxin B 1 to a reactive derivative toxic to Salmonella typhimurium TA 1530. Cancer Res 1972; 32: 2058–2066.
[79] Foster PL, Eisenstadt E & Miller JH. Base substitution mutations induced by metabolically activated aflatoxin B1. Proc Natl Acad Sci USA 1983; 80: 2695–2698.
[80] Bressac B, Kew M, Wands J & Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350: 429–431.
[81] Hsu IC, Metcalf RA, Sun T et al. Mutational hotspot in the p53 gene in human hepatocellular carcinomas.Nature 1991; 350: 427–428.
[82] Qian GS, Ross RK, Yu MC et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People’s Republic of China. Cancer Epidemiol Biomarkers Prev 1994; 3: 3–10.
[83] Ming L, Thorgeirsson SS, Gail MH et al. Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology 2002; 36: 1214–1220.
[84] Yu SZ. Primary prevention of hepatocellular carcinoma. J Gastroenterol Hepatol 1995; 10: 674–682.
[85] Turner PC, Sylla A, Diallo MS, Castegnaro JJ et al. The roles of aflatoxins and hepatitis viruses in the etiopathogenesis of hepatocellular carcinoma: a basis for primary prevention in Guinea-Conakry, West Africa. J Gastroenterol Hepatol 2002; 17: S441–S448.
[86] IARC Monographs, Hepatitis Viruses, vol. 59. Lyon: IARC Press; 1994 p. 72–97.
[87] Chou YH, Chiou HJ, Tiu CM et al. Duplex doppler ultrasound of hepatic schistosomiasis japonica: a study of 47 patients. Am J Trop Med Hyg 2003; 68: 18–23.
[88] Fox JG, Dewhirst FE, Tully JG, Paster BJ, Yan L, Taylor NS, Collins MJ Jr, Gorelick PL, Ward JM. Helicobacter hepaticus sp. nov., a microaerophilic bacterium isolated from livers and intestinal mucosal scrapings from mice. J Clin Microbiol. 1994 May; 32(5):1238-45.
[89]宣世英,李宁,战淑慧,强新.原发性肝癌组织中螺杆菌属16S rRNA基因的检测及意义.中华传染病杂志, 2006, 24(6): 396- 400.
[90] Nair S, Mason A, Eason J, Loss G & Perrillo RP. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 2002; 36: 150–155.
[91] Calle EE, Rodriguez C, Walker-Thurmond K & Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003; 348: 1625–1638.
[92] Regimbeau JM, Colombat M, Mognol P, Durand F, Abdalla E, Degott C, De gos F, Farges O & Belghiti J.Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 2004; 10: S69–S73.
[93] Ratziu V, Bonyhay L, Di Martino V,et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002; 35: 1485–1493.
[94] Calle EE, Rodriguez C, Walker-Thurmond K & Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003; 348: 1625–1638.
[95] Weiderpass E, Gridley G, Nyren O, Pennello G, Landstrom AS & Ekbom A. Cause-specific mortality in a cohort of patients with diabetes mellitus: a population-based study in Sweden. J Clin Epidemiol 2001; 54:802–809.
[96] Adami HO, Chow WH, Nyren O et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 1996; 88: 1472–1477.
[97] Kalk H. The relationship between fatty liver and diabetes mellitus. Ger Med Mon 1960; 5: 81–84.
[98] Mason AL, Lau JY, Hoang N et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 29: 328–333.
[99] Petrides AS & Defronzo RA. Glucose and insulin metabolism in cirrhosis. J Hepatol 1989; 8: 107–114.
[100] Nussbaum T, Samarin J, Ehemann V,et al. Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis. Hepatology 2008; 48:146–156.
[101] El Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006; 4:369–380.
[102] Florez JC. Clinical review: the genetics of type 2 diabetes: a realistic appraisal in 2008. J Clin Endocrinol Metab 2008; 93:4633–4642.
[103] Salanti G, Southam L, Altshuler D, Ardlie K, Barroso I, Boehnke M, et al.Underlying genetic models of inheritance in established type 2 diabetes associations. Am J Epidemiol 2009; 170:537-545.
[104] Adami HO, Chow WH, Nyren O, Berne C, Linet MS, Ekbom A, et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 1996; 88:1472–1477.
[105] Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002; 36:1206–1213.
[106] Hjalgrim H, Frisch M, Ekbom A, Kyvik KO, Melbye M, Green A. Cancer anddiabetes– a follow-up study of two population-based cohorts of diabetic patients. J Intern Med 1997; 241:471–475.
[107] Rapp K, Schroeder J, Klenk J, et al. Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria.Br J Cancer 2005;93:1062–1067.
[108] Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight,obesity and mortality from cancer in a prospective studied cohort of US adults. N Engl J Med 2003; 348:1625–1638.
[109] Samanic C, Gridley G, Chow WH, et al. Obesity and cancer riskamong white and black United States veterans. Cancer Causes Control 2004; 15:35–43.
[110] Lai MS, Hsieh MS, Chiu YH, et al. Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection. Hepatology 2006; 43:1295–1302.
[111] El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk ofchronic liver disease and hepatocellular carcinoma. Gasteroenterology 2004; 126:460–468.
[112] Davila JA, Morgan RO, Shaib Y, et al. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005; 54:533–539.
[113] CHI–LING CHEN,* HWAI–I YANG, WEI–SHIUNG YANG,et al. Metabolic Factors and Risk of Hepatocellular Carcinoma by Chronic Hepatitis B/C Infection: A Follow-up Study in Taiwan. GASTROENTEROLOGY 2008;135:111–121
[114] Hemminki K, Li X. Familial liver and gall bladder cancer: a nationwide epidemiological study from Sweden. Gut 2003; 52:592–596.
[115] McGlynn KA, Hunter K, Levoyer T et al. Susceptibility to aflatoxin B1-related primary hepatocellular carcinoma in mice and humans. Cancer Res 2003; 63: 4594–4601.
[116] Huang YS, Chern HD,Wu JC et al. Polymorphism of the N-acetyltransferase 2 gene, red meat intake, and the susceptibility of hepatocellular carcinoma. Am J Gastroenterol 2003; 98: 1417–1422.
[117] Yeh SH, Chang CF, Shau WYet al. Dominance of functional androgen receptor allele with longer CAG repeat in hepatitis B virus-related female hepatocarcinogenesis. Cancer Res 2002; 62: 4346–4351.
[118] Frisch M, Biggar RJ, Engels EA, Goedert JJ & AIDS-Cancer Match Registry Study Group. Association of cancer with AIDS-relatedimmunosuppression in adults. JAMA 2001; 285: 1736–1745.
[119] Darby SC, Ewart DW& Giangrande PL. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors’Organisation. Lancet 1997; 350: 1425–1431.
[120] Thio CL. Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment. Semin Liver Dis 2003; 23: 125–136.
[121] Elzouki AN, Eriksson S. Risk of hepatobiliary disease in adults with severe alpha 1-antitrypsin deficiency (PiZZ): is chronic viral hepatitis B or C an additional risk factor for cirrhosis and hepatocellular carcinoma? Eur J Gastroenterol Hepatol 1996; 8:989–994.
[122] Alexander J, Kowdley KV. HFE-associated hereditary hemochromatosis.Genet Med 2009; 11:307–313.
[123] Olynyk JK, Trinder D, Ramm GA, Britton RS, Bacon BR. Hereditary hemochromatosis in the post-HFE era. Hepatology 2008;48:991–1001.
[124] Elmberg M, Hultcrantz R, Ekbom A, Brandt L, Olsson S, Olsson R, et al. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 2003; 125:1733–1741.
[125] Seth AK, Badminton MN, Mirza D, Russell S, Elias E. Liver transplantation for porphyria: who, when, and how? Liver Transpl 2007; 13:1219–1227.
[126] Andant C, Puy H, Bogard C, Faivre J, Soule JC, Nordmann Y, et al.Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors. J Hepatol 2000;32:933–939.
[127] Aarsand AK, Boman H, Sandberg S. Familial and sporadic porphyriacutanea tarda: characterization and diagnostic strategies. Clin Chem2009; 55:795–803.
[128] Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol 2003;39:620–627.
[129] Hassan MM, Kaseb A, Li D, Patt YZ, Vauthey JN, Thomas MB, et al. Association between hypothyroidism and hepatocellular carcinoma: a case–control study in the United States. Hepatology 2009; 49:1563–1570.
[130] Liangpunsakul S, Chalasani N. Is hypothyroidism a risk factor for nonalcoholic steatohepatitis? J Clin Gastroenterol 2003; 37:340–343.
[131] Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, Tokushige K, et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol 2009; 44 (Suppl. 19):89–95.
[132] Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R, et al. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 2007; 11:119–132.
[133] Hill-Baskin AE, Markiewski MM, Buchner DA, Shao H, Desantis D, Hsiao G, et al. Diet-induced hepatocellular carcinoma in genetically-predisposed mice. Hum Mol Genet 2009; 18:2975–2988..
[134] Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533–543. CDC. Geographic Distribution of Chronic HBV Infection. Hepatitis B Slide Set (Internet) 2002.
[135] Hann HL, Kim C, London WT et al. Hepatitis B virus and primary hepatocellular carcinoma: family Studies in Korea. Int J Cancer 1982; 30: 47–51.
[136] Evans AA, Chen G, Ross EA et al. Eight-year follow-up of the 90,000-person Haimen City Cohort: I.Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol Biomarkers Prev 2002; 11: 369–376.
[137] CDC. Global progress toward universal childhood hepatitis B vaccination, 2003. MMWR 2003; 52: 868–869.
[138] Beasley RP. Hepatitis B virus, the major etiology of hepatocellular carcinoma. Cancer 1988; 61: 1942–1956.
[139] Man-Fung Yuen, Yasuhito Tanaka, Daniel Yee-Tak Fong,et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. Journal of Hepatology 50 (2009) 80–88
[140] Jaw-Ching Wu, Yi-Hsiang Huang, Gar-Yang Chau,et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. Journal of Hepatology 51 (2009) 890–897
[141] Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al.Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351:1521–1531.
[142] Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006; 44:1543–1554.
[143] Ahn JY, Jung EY, Kwun HJ,et al. Dual effects of hepatitis b virus X protein on the regulation of cell-cycle control depending on the status of cellular p53. J Gen Virol. 2002 Nov; 83(Pt11):2765-2772.
[144] Niederau C, Lange S, Heintges T et al. Prognosis of chronic hepatitis C:results of a large prospective cohort study. Hepatology 1998; 28: 1687–1695.
[145] Tagger A, Donato F, Ribero ML et al. Case–control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: the role of HCV genotypes and the synergism with hepatitis B virus and alcohol. Brescia HCC Study. Int J Cancer 1999; 81: 695–699.
[146] M. Levrero, Viral hepatitis and liver cancer: the case of hepatitis C, Oncogene 25 (27) (2006) 3834–3847.
[147] L. Golden-Mason, H.R. Rosen, Natural killer cells: primary target for hepatitis C virus immune evasion strategies? Liver Transplant. 12 (3) (2006) 363–372.
[148] H.J. Alter, L.B Seeff, Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome, Semin. Liver Dis. 20 (2000) 17–35. J.M. Pawlotsky, Diagnostic tests for hepatitis C, J. Hepatol. 31 (Suppl. 1) (1999) 71–79.
[149] D.G. Bowen, C.M. Walker, Adaptive immune responses in acute and chronic hepatitis C virus infection, Nature 436(7053) (2005) 946–952.
[150] R. Thimme, D. Oldach, K.M. Chang, C. Steiger, S.C. Ray, F.V.Chisari, Determinants of viral clearance and persistence during acute hepatitis C virus infection, J. Exp. Med. 194(10) (2001) 1395–1406.
[151] J.J. Chang, S.R. Lewin, Immunopathogenesis of hepatitis B virus infection, Immunol. Cell Biol. 85 (1) (2007) 16–23.
[152] M.P. Manns, J.G. McHutchison, S.C. Gordon, et al., Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: arandomised trial, Lancet 358 (2001) 958–965.
[153] A. Aghemo, M.G. Rumi, S. Monico, et al.The pattern of pegylated interferon alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype, Antivir. Ther. 14 (4) (2009) 577–584.
[154] P. Marotta, D. Hueppe, E. Zehnter, P. Kwo, I. Jacobson, Efficacy of chronic hepatitis C therapy in community-based trials, Clin. Gastroenterol. Hepatol. 7 (10) (2009) 1028–1036.
[155] Donato F, Ooffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer. 1998 Jan 30; 75(3):347-354.
[156] Befeler AS, DiBisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002; 122:1609–1619.
[157] Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology 2000; 31: 241–246.
[158] Bellentani S, Tiribelli C, Saccoccio G et al. Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study. Hepatology 1994; 20: 1442–1449.
[159] Bellentani S & Tiribelli C. The spectrum of liver disease in the general population: lesson from the Dionysos study. J Hepatol 2001; 35: 531–537.
[160] Velazquez RF, Rodriguez M, Navascues CA et al. Prospective analysis of risk factors for hepatocellularcarcinoma in patients with liver cirrhosis. Hepatology 2003; 37: 520–527.
[161] Friedman S, Schiano T. Cirrhosis and its sequelae. In: Goldman L, Ausiello D, eds. Cecil Textbook of Medicine. 22nd ed. Philadelphia, Pa.: Saunders, 2004:936-44.
[162] Crawford JM. Liver and biliary tract. In: Kumar V, Abbas AK, Fausto N, eds. Robbins and Cotran Pathologic Basis of Disease. 7th ed. Philadelphia, Pa.: Elsevier Saunders, 2005:877-938.
[163] Wu F,Chen WZ,Bai J,et a1.Tumor vessel destruction resulting from high intensity focused ultrasound in patients with solid malignancies[J].Ultra.sound Med Biol,2002,28(4):535-542.
[164] Gschwantler M, Vavrik J, Gebauer A, Kriwanek S, Schrutka-K?lbl C, Fleischer J, Madani B, Brownstone E, Tscholakoff D, Weiss W. Course of platelet counts in cirrhotic patients after implantation of a transjugular intrahepatic portosystemic shunt--a prospective, controlled study. J Hepatol 1999 Feb; 30(2):254-9.
[165] Ba?ares R, Nú?ez O, Escudero M, Fernández C, Vaquero J, Beceiro I, Echenagusía A, Clemente G, Santos L. Patients with cirrhosis and bare-Stent TIPS may have increased risk of hepatocellular carcinoma. Hepatology. 2005 Jul; 42(1):236.
[166] Yasuhiko Sugawara, MD, Junji Yamamoto, MD, Kazuaki Shimada, MD,et al. Splenectomy in Patients with Hepatocellular Carcinoma and Hypersplenism. J Am Coll Surg.2000 April; 190(4):446-450.
[167]王宇.门静脉高压症的外科治疗.中华外科杂志.2005,10;43(19):1234-1236.
[168]汪谦,夏穗生,姜汉英,等.脾脏及Tuftsin在肝硬化形成过程免疫调控机制探讨[J].中华医学杂志,1995,75(10):594-8.
[169] Fridkin M,Gottlieb P.Tuftsin,Thr-Lys-Pro-Arg[J].Mol cell Biochem,1981,41(1):73-77.
[170]王洪波,周宁新,李志伟,等.门脉高压患者脾切除术后免疫功能的改变及其与脾组织免疫细胞的关系.消化外科,2004,3(4):286-290.
[171]刘俊卯,端木浩,丁海.脾切除对肝炎后肝硬化门脉高压症免疫功能的影响.中华医学丛刊,2003,3:13-14.
[172]吴仕和,仇登波,黄韬.门脉高压症患者脾脏免疫学研究[ J ] .湖南医学, 2001 , 18 (1) :124.
[173]汪谦,程庆君,郭全鹏.门脉高压巨脾原位保留和异位移植组织变化与功能比较[J ] .蚌埠医学院学报, 1991 , 16 (1) :55256.
[174]吴厚慧,徐鹿平,刘凤强,等.肝硬化巨脾切除对免疫功能的影响.肝胆胰脾外科杂志.2000,12(2):18-20.
[175]曹志新,陈孝平,吴在德.肝癌合并肝硬化患者脾脏Thl/Th2细胞因子免疫状态的研究.中华实验外科杂志.2001, 11(18): 518- 519.
[176]王新,陈岳祥,许才绂,赵国宁,黄裕新,王庆莉.肿瘤坏死因子α与人肝纤维化关系的研究.华人消化杂志,1998,6(2):106—108.
[177] Murata K, Shiraki K, Sugimoto K, Takase K, Nakano T, Furusaka A, Tameda Y.Splenectomy enhances liver regeneration through tumor necrosis factor (TNF)-alpha following dimethylnitrosamine-induced cirrhotic rat model.Hepatogastroenterology. 2001 Jul-Aug;48(40):1022-7.
[178]彭建平,叶德存,顾霞,等.脾切除影响肝硬变的机理探讨.中国普外基础与临床杂志.2003,10(3):222-225.
[179] Cho JJ, Hocher B, Herbst H, Jia JD, Ruehl M, Hahn EG, Riecken EO, Schuppan D.An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis. Gastroenterology. 2000 Jun;118(6):1169-78.
[180] Nagasue N, Dhar DK, Yamanoi A, Emi Y, Udagawa J, Yamamoto A, Tachibana M, Kubota H, Kohno H, Harada T.Production and release of endothelin-1 from the gut and spleen in portal hypertension due to cirrhosis. Hepatology. 2000 May; 31(5):1107-1114.
[181]陈黎明,王陆军。张鸿飞,程云,辛绍杰,陈菊梅,张晓峰.肝硬化患者脾切除术前后血清血小板衍生生长因子—AB检测分析.中华肝脏病杂志,2003,11:748.
[182]陆新良,朱志鑫,蔡建庭,唐训球,钱可大,周君富.脾切除有助于纠正肝硬化患者氧化和抗氧化的失衡.临床肝胆病杂志,2002,18(5):313-315.
[183] BrittonRS,Bacon BR.Role of free radicals in liver diseases and hepatic fibrosis[J].Hepatogastroenterology,1994,41(4):343—8.
[184] Oh JW, Ahn SM, Kim KS, Choi JS, Lee WJ, Kim BR. The role of splenectomy in patients with hepatocellular carcinoma and secondary hypersplenism.Yonsei Med J. 2003 Dec 30; 44(6):1053-8。
[185]汪谦,彭慧,黄洁夫.门静脉高压病理脾切除疗效分析与远期随访.中华肝胆外科杂志,2000,6:21-23.
[186] Sekiguchi T, Nagamine T, Takagi H, Mori M. Reduction of virus burden-induced splenectomy in patients with liver cirrhosis related to hepatitis C virus infection. World J Gastroenterol 2006;12(13):2089–94. 7.
[187] Magdy M.A. Elsebae*, Nadia B. Abu-Zekri. A study of the effect of splenectomy on hepatic functional reserve and structural damage in patients with chronic hepatitis C virus infection by non-invasive serum markers. A prospective study. International Journal of Surgery 6 (2008) 362–366.
[188]刘支援,何兴舟.近十年来病例对照研究方法的应用.国外医学卫生学分册,1987,2:88—91.
[189]陈延,詹思延,李立明.病例对照研究发展历史.中华流行病学杂志.2004,3;25(3):273-275.
[190] Rosenbaum PR, Rubin DB. The central role of the propensity score inobservational studies for causal effects. Biometrika 1983; 70:41–55.
[191] Cochran WG. The effectiveness of adjustment by Subclassification in removing bias in observational studies. Biometrics , 1968 , 24∶295-313.
[192] Katherine HH ,Thomas AL. Propensity score modeling strategies for the causal analysis of observational data. Biostatistics , 2002 , 2∶179-193.
[193]汪涛,山口拓洋,大桥靖雄,等.倾向指数方法的蒙特卡罗研究.中华流行病学杂志.2005,6;26(6):458-462.
[194] Velázquez RF, Rodríguez M, Navascués CA, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis[J]. Hepatology, 2003, 37(3): 520-527.
[195]韩国庆,秦成勇,任万华,等.γ-谷氨酰转移酶mRNA亚型对肝细胞癌变的监测[J].中华内科杂志, 2002,41(3):160-162.
[196] Takayashiki T, Yoshidome H, Kimura F, et al. Increased expression of toll-like receptor 4 enhances endotoxin-induced hepatic failure in partially hepatectomized mice[J]. J Hepatol , 2004, 41(4): 621-628.
[197] Takashi Kumada*, Hidenori Toyoda, Seiki Kiriyama, et al. Incidence of hepatocellular carcinoma in hepatitis C carriers with normal alanine aminotransferase levels[J]. Journal of Hepatology, 2009, 50: 729–735.
[198] Magdy M.A. Elsebae*, Nadia B. Abu-Zekri. A study of the effect of splenectomy on hepatic functional reserve and structural damage in patients with chronic hepatitis C virus infection by non-invasive serum markers. A prospective study [J]. International Journal of Surgery, 2008, 16: 362–366.
[199] J.L. Rodri′guez-Di′az*, V. Rosas-Camargo*, O. Vega-Vegaz , et al. Clinical and Pathological Factors Associat-ed the Development of Hepatocellular Carcinoma in Patients with Hepatitis Virus-relatedCirrhosis: A long-term Follow-up Study[J]. Clinical Oncology , 2007,19: 197-203.
[200] Ve la′zquez R, Rodr?′guez M, Navascue′s CA, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis[J]. Hepatology, 2003, 37: 520-527.
[2] Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet2003;362:1907–1917.
[3] CDC. Geographic Distribution of Chronic HBV Infection. Hepatitis B Slide Set (Internet) 2002.
[4]梁晓峰,陈园生,王晓军,贺雄,陈丽娟,王骏,林长缨,白呼群,严俊,崔钢,于竞进.中国3岁以上人群乙型肝炎血清流行病学研究.中华流行病学杂志2005,9;26(9).
[5] Velázquez RF, Rodríguez M, Navascués CA, Linares A, Pérez R, Sotorríos NG, Martínez I, Rodrigo L. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003 Mar;37(3):520-7.
[6] Peck-Radosavljevic M.Hypersplenism. Eur J Gastroenterol Hepatol 2001 Apr;13(4):317-23.
[7] Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533–543.
[8] McGlynn KA, Tsao L, Hsing AW, Devesa SS & Fraumeni Jr. JF. International trends and patterns of primary liver cancer. Int J Cancer 2001; 94: 290–296.
[9] Man-Fung Yuen1, Yasuhito Tanaka2, Daniel Yee-Tak Fong3,et al. Independent risk factors and predictive score for the development ofhepatocellular carcinoma in chronic hepatitis B. Journal of Hepatology. 2009;50:80–88.
[10] J.L. Rodri′guez-Di′az*, V. Rosas-Camargo*, O. Vega-Vegaz , et al. Clinical and Pathological Factors Associat-ed the Development of Hepatocellular Carcinoma in Patients with Hepatitis Virus-related Cirrhosis: A long-term Follow-up Study. Clinical Oncology 2007;19: 197-203.
[11] Parkin DM, Whelan SL, Ferlay J, Teppo L & Thomas DB (eds.) Cancer Incidence in Five Continents IARC Scientific Publications No. 155, vol. VIII. Lyon: IARC Press, 2002.
[12] Katherine A. McGlynn* PhD. Epidemiology and natural history of hepatocellular carcinoma. Best Practice & Research Clinical Gastroenterology.Vol. 19, No. 1, pp. 3–23, 2005
[13] J.L. Rodri′guez-Di′az*, V. Rosas-Camargo*, O. Vega-Vegaz , et al. Clinical and Pathological Factors Associat-ed the Development of Hepatocellular Carcinoma in Patients with Hepatitis Virus-related Cirrhosis: A long-term Follow-up Study. Clinical Oncology 2007;19: 197-203.
[14] Tanaka K, Hirohata T, Takeshita S, Hirohata I, Koga S,Sugimachi K, et al. Hepatitis B virus, cigarette smoking and alcohol consumption in the development of hepatocellular carcinoma: a case-control study in Kukuoka, Japan. Int J Cancer
[15] Jorge A. Marrero*, Robert J. Fontana, Sherry Fu.etal. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. Journal of Hepatology.2005;42: 218–224.
[16] Donato F, Tagger A, Chiesa R, Ribero ML, Tomasoni V, Fasola M, etal.Hepatitis B and C virus infection, alcohol drinking and hepatocellular carcinoma: a case-control study in Italy. Hepatology.1997;26:579–584.
[17]范宗华,褚天新,范宗林,等.饮酒与消化道肿瘤死亡关系的队列研究[J].现代预防医学,1996,23(1):20-22.
[18] Agudo A, Ahrens W, Benhamou E, Benhamou S, Boffetta P,Darby SC, et al. Lung cancer and cigarette smoking in women: a multicenter case-control study in Europe. Int J Cancer 2000;88:820–827.
[19] Oshima A, Tsukuma H, Hiyama T, Fujimoto I, Yamano H & Tanaka M. Follow-up study of HBsAg-positive blood donors with special reference to effect of drinking and smoking on development of liver cancer. Int J Cancer 1984; 34: 775–779.
[20] Yu MW, Hsu FC & Sheen IS. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 1997; 145: 1039–1047.
[21] Aizawa Y, Shibamoto Y, Takagi I, Zeniya M & Toda G. Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. Cancer 2000; 89: 53–59.
[22] Donato F, Tagger A, Gelatti U et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002; 155: 323–331.
[23] McCoy GD, Hecht SS, Katayama S &Wynder EL. Differential effect of chronic ethanol consumption on the carcinogenicity of N-nitroso-pyrrolidine and N0-nitrosonornicotine in male Syrian golden hamsters. Cancer Res 1981; 41: 2849–2854.
[24] Seitz HK, Poschl G & Simanowski UA. Alcohol and cancer. Recent Development Alcoholism 1998; 14: 67–95.
[25] Yu SY, Zhu YJ, LiWG et al. A preliminary report on the intervention trials of primary liver cancer in high risk populations with nutritional supplementation of selenium in China. Biol Trace Elem Res 1991; 29: 289–294.
[26] Yu MW, Horng IS, Hsu KH, Chiang YC, Liaw YF & Chen CJ. Plasma selenium levels and risk of hepatocellular carcinoma among men with chronic hepatitis infection. Am J Epidemiol 1999; 150: 367–374.
[27] Hsing AW, GwoW, Chen J, Stone BJ, BlotWJ & Fraumeni Jr. JF. Correlates of liver cancer mortality in China. Int J Epidemiol 1991; 20: 54–59.
[28] Klaunig JE. Chemopreventive effects of green tea components on hepatic carcinogenesis. Prev Med 1992;21: 510–519.
[29] Evans AA, Chen G, Ross EA et al. Eight-year follow-up of the 90,000-person Haimen City Cohort: Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol Biomarkers Prev 2002; 11: 369–376.
[30] Mu LN, Zhou XF, Ding BG et al. A case-control study on drinking green tea and decreasing risk of cancers in the alimentary canal among cigarette smokers and alcohol drinkers. Zhonghua Liu Xing Bing Xue Za Zhi 2003; 24: 192–195.
[31] World Cancer Research Fund, American Institute for cancer research, Liver In Food, Nutrition and the Prevention of Cancer: A Global Perspective. Washington, DC: American Institute for Cancer Research; 1997 pp. 202–214.
[32] Lopez-Garcia E, van Dam RM, Li TY, Rodriguez-Artalejo F, Hu FB. The relationship of coffee consumption with mortality. Ann Intern Med2008;148:904-914.
[33] Ruhl CE, Everhart JE. Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2005;128:24-32.
[34] Klatsky AL, Morton C, Udaltsova N, Friedman GD. Coffee, cirrhosis, and transaminase enzymes. Arch Intern Med 2006;166:1190-1195.
[35] Tanaka K, Tokunaga S, Kono S, et al. Coffee consumption and decreased serum gamma-glutamyltransferase and aminotransferase activities among male alcohol drinkers. Int J Epidemiol 1998;27:438-443.
[36] Casiglia E, Spolaore P, Ginocchio G, Ambrosio GB. Unexpected effects of coffee consumption on liver enzymes. Eur J Epidemiol 1993;9:293-297.
[37] Kono S, Shinchi K, Imanishi K, Todoroki I, Hatsuse K. Coffee and serumgamma-glutamyltransferase: a study of self-defense officials in Japan. Am J Epidemiol 1994;139:723-727.
[38] Honjo S, Kono S, Coleman MP, et al. Coffee drinking and serum gammaglutamyltransferase:an extended study of Self-Defense Officials of Japan. Ann Epidemiol 1999;9:325-331.
[39] Honjo S, Kono S, Coleman MP, et al. Coffee consumption and serum aminotransferases in middle-aged Japanese men. J Clin Epidemiol 2001;54:823-829.
[40] Corrao G, Zambon A, Bagnardi V, D’Amicis A, Klatsky A. Coffee, caffeine,and the risk of liver cirrhosis. Ann Epidemiol 2001;11:458-465.
[41] Tverdal A, Skurtveit S. Coffee intake and mortality from liver cirrhosis.Ann Epidemiol 2003;13:419-423.
[42] Gelatti U, Covolo L, Franceschini M, Pirali F, Tagger A, Ribero ML, et al.Coffee consumption reduces the risk of hepatocellularcarcinomaindependently of its aetiology: a case-control study. J Hepatol 2005;42:528-534.
[43] Inoue M, Yoshimi I, Sobue T, Tsugane S. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. J Natl Cancer Inst 2005;97:293-300.
[44] Shimazu T, Tsubono Y, Kuriyama S, et al. Coffee consumption and the risk of primary liver cancer: pooled analysis of two prospective studies in Japan. Int J Cancer 2005;116:150-154
[45] Gallus S, Bertuzzi M, Tavani A, Bosetti C, Negri E, La Vecchia C, et al.Does coffee protect against hepatocellular carcinoma? Br J Cancer 2002; 87:956-959.
[46] Bravi F, Bosetti C, Tavani A, et al. Coffee drinking and hepatocellular carcinoma risk: a metaanalysis.Hepatology 2007;46:430-435.
[47] Larsson SC, Wolk A. Coffee consumption and risk of liver cancer: a meta analysis.Gastroenterology 2007;132:1740-1745.
[48] Apurva A. Modi, Jordan J. Feld, Yoon Park. Increased Caffeine Consumption Is Associated with Reduced Hepatic Fibrosis. Hepatology 2010;51:201-209.
[49] McGlynn KA, Tsao L, Hsing AW, Devesa SS & Fraumeni Jr. JF. International trends and patterns of primary liver cancer. Int J Cancer 2001; 94: 290–296.
[50] Tagger A, Donato F, Ribero ML et al. Case–control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: the role of HCV genotypes and the synergism with hepatitis B virus and alcohol. Brescia HCC Study. Int J Cancer 1999; 81: 695–699.
[51] Linet MS, Gridley G, Nyren O et al. Primary liver cancer, othermalignancies, and mortality risks following porphyria: a cohort study in Denmark and Sweden. Am J Epidemiol 1999; 149: 1010–1015.
[52] Gordeuk VR, McLaren CE, Macphail AP, Deichsel G & Bothwell TH. Associations of iron overload in Africa with hepatocellular carcinoma and tuberculosis: Strachan’s 1929 thesis revisited. Blood 1996; 87:3470–3476.
[53] Nagasue, N., Kohno, H., 1992. Hepatocellular carcinoma and sex hormones. HPB-Surg. 6, 1–6.
[54] Collaborative Milts Project Team. Oral contraceptives and liver cancer. Contraception 1997; 56: 275–284.
[55] Hannaford PC, Kay CR, Vessey MP, Painter R & Mant J. Combined oral contraceptives and liver disease.Contraception 1997; 55: 145–151.
[56] WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Depot-medroxyprogesterone acetate (DMPA) and risk of liver cancer. Int J Cancer 1991; 49: 182–185.
[57] . Soe KL, Soe M & Gluud CN. Liver pathology associated with the use of anabolic–androgenic steroids. Liver 1992; 12: 73–79.
[58] IARC Monographs, Overall Evaluations Of Carcinogenicity: An Updating of IARC Monographs, vol. 1–42, supplement 7. Lyon: IARC Press; 1987.
[59] De Maria N, Manno M & Villa E. Sex hormones and liver cancer. Mol Cell Endocrinol 2002; 193: 59–63.
[60] Yu MW& Chen CJ. Elevated serum testosterone levels and risk of hepatocellular carcinoma. Cancer Res 1993; 53: 790–79.
[61] Yuan JM, Ross RK, Stanczyk FZ et al. A cohort study of serum testosterone and hepatocellular carcinoma in Shanghai, China. Int J Cancer 1995; 63: 491–493.
[62] La Vecchia C, Negri E, Franceschi S & D’avanzo B. Reproductive factorsand the risk of hepatocellular carcinoma in women. Int J Cancer 1992; 52: 351–354.
[63] HsingAW, McLaughlin JK, Hoover RN, Co Chien HT, BlotWJ & Fraumeni Jr. JF. Parity and primary liver cancer among young women. J Natl Cancer Inst 1992; 84: 1118–1119.
[64] Cole P, MacMahon B & Brown JB. Oestrogen profiles of parous and nulliparous women. Lancet 1976; 2:596–599.
[65] Mucci LA, Kuper HE, Tamimi R, Lagiou P, Spanos E & Trichopoulos D. Age at menarche and age at menopause in relation to hepatocellular carcinoma in women. BJOG 2001; 108: 291–294.
[66] Von Kaick, G., Wesch, H., 1984. Follow-up study. In: Von Kaick, G., Muth, A., Kaul, A. (Eds.), The German Thorotrast Study. Commission of the Europe on Communities, Luxembourg, pp. 190–211.
[67] Mori T, Fukutomi K, Kato Y et al. 1998 results of the first series of follow-up studies on Japanese Thorotrast patients and their relationships to an autopsy series. Radiat Res 1999; 152: S72–S80.
[68] Wong RH, Chen PC, Du CL, Wang JD & Cheng TJ. An increased standardized mortality ratio for liver cancer among polyvinyl chloride workers in Taiwan. Occup Environ Med 2002; 59: 405–409.
[69] Chiou H-Y, Hsueh Y-M, Liaw K-F et al. Incidence of internal cancers and ingested inorganic arsenic: a seven-year follow-up study in Taiwan. Cancer Res 1995; 55: 1296–1300.
[70] Lewis DR, Southwick JW, Ouellet-Hellstrom R, Rench J & Calderon RL. Drinking water arsenic in Utah: a cohort mortality study. Environ Health Perspect 1999; 107: 359–365.
[71]苏德隆.饮水中蓝绿藻毒素与肝癌的研究〔J〕.医学研究通讯, 2001,30(6): 19- 20.
[72] Park H, Namikoshi M, Brittain SM, Carmichael WW, Murphy T. Microcystin-LR, a new microcystin isoplated from waterbloom in a Canadian prairie lake. Toxicon. 2001 Jun;39(6):855-62.
[73]胡志坚,陈华,庞春艳,林其英.微囊藻毒素对肝细胞凋亡相关基因表达的影响〔J〕.中华预防医学杂志, 2007, 41(1): 13- 16.
[74]周珏平,沈建国,童建.微囊藻毒素LR对小鼠肝脏和淋巴细胞的损伤效应〔J〕.环境与职业医学, 2003, 20(1): 41- 42.
[75] Zegura B, Sedmak B, Filipic M.Microeystin LR induces oxidative DNA damage in human hepatoma cell line HepG2. Toxicon. 2003 Jan;41(1):41-8
[76] Shun-Zang, Y., 1990. Drinking water and primary liver cancer. In: Tang, Z.Y., Wo, M.C., Yia, S.S. (Eds.), Primary Liver Cancer. Springer-Verlaag, Berlin, pp. 30–37.
[77] Colombo, M., 1992. Hepatocellular carcinoma. J. Hepatol. 15, 225–236.
[78] Garner RC, Miller EC & Miller JA. Liver microsomal metabolism of aflatoxin B 1 to a reactive derivative toxic to Salmonella typhimurium TA 1530. Cancer Res 1972; 32: 2058–2066.
[79] Foster PL, Eisenstadt E & Miller JH. Base substitution mutations induced by metabolically activated aflatoxin B1. Proc Natl Acad Sci USA 1983; 80: 2695–2698.
[80] Bressac B, Kew M, Wands J & Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350: 429–431.
[81] Hsu IC, Metcalf RA, Sun T et al. Mutational hotspot in the p53 gene in human hepatocellular carcinomas.Nature 1991; 350: 427–428.
[82] Qian GS, Ross RK, Yu MC et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People’s Republic of China. Cancer Epidemiol Biomarkers Prev 1994; 3: 3–10.
[83] Ming L, Thorgeirsson SS, Gail MH et al. Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology 2002; 36: 1214–1220.
[84] Yu SZ. Primary prevention of hepatocellular carcinoma. J Gastroenterol Hepatol 1995; 10: 674–682.
[85] Turner PC, Sylla A, Diallo MS, Castegnaro JJ et al. The roles of aflatoxins and hepatitis viruses in the etiopathogenesis of hepatocellular carcinoma: a basis for primary prevention in Guinea-Conakry, West Africa. J Gastroenterol Hepatol 2002; 17: S441–S448.
[86] IARC Monographs, Hepatitis Viruses, vol. 59. Lyon: IARC Press; 1994 p. 72–97.
[87] Chou YH, Chiou HJ, Tiu CM et al. Duplex doppler ultrasound of hepatic schistosomiasis japonica: a study of 47 patients. Am J Trop Med Hyg 2003; 68: 18–23.
[88] Fox JG, Dewhirst FE, Tully JG, Paster BJ, Yan L, Taylor NS, Collins MJ Jr, Gorelick PL, Ward JM. Helicobacter hepaticus sp. nov., a microaerophilic bacterium isolated from livers and intestinal mucosal scrapings from mice. J Clin Microbiol. 1994 May; 32(5):1238-45.
[89]宣世英,李宁,战淑慧,强新.原发性肝癌组织中螺杆菌属16S rRNA基因的检测及意义.中华传染病杂志, 2006, 24(6): 396- 400.
[90] Nair S, Mason A, Eason J, Loss G & Perrillo RP. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 2002; 36: 150–155.
[91] Calle EE, Rodriguez C, Walker-Thurmond K & Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003; 348: 1625–1638.
[92] Regimbeau JM, Colombat M, Mognol P, Durand F, Abdalla E, Degott C, De gos F, Farges O & Belghiti J.Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 2004; 10: S69–S73.
[93] Ratziu V, Bonyhay L, Di Martino V,et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002; 35: 1485–1493.
[94] Calle EE, Rodriguez C, Walker-Thurmond K & Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003; 348: 1625–1638.
[95] Weiderpass E, Gridley G, Nyren O, Pennello G, Landstrom AS & Ekbom A. Cause-specific mortality in a cohort of patients with diabetes mellitus: a population-based study in Sweden. J Clin Epidemiol 2001; 54:802–809.
[96] Adami HO, Chow WH, Nyren O et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 1996; 88: 1472–1477.
[97] Kalk H. The relationship between fatty liver and diabetes mellitus. Ger Med Mon 1960; 5: 81–84.
[98] Mason AL, Lau JY, Hoang N et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 29: 328–333.
[99] Petrides AS & Defronzo RA. Glucose and insulin metabolism in cirrhosis. J Hepatol 1989; 8: 107–114.
[100] Nussbaum T, Samarin J, Ehemann V,et al. Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis. Hepatology 2008; 48:146–156.
[101] El Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006; 4:369–380.
[102] Florez JC. Clinical review: the genetics of type 2 diabetes: a realistic appraisal in 2008. J Clin Endocrinol Metab 2008; 93:4633–4642.
[103] Salanti G, Southam L, Altshuler D, Ardlie K, Barroso I, Boehnke M, et al.Underlying genetic models of inheritance in established type 2 diabetes associations. Am J Epidemiol 2009; 170:537-545.
[104] Adami HO, Chow WH, Nyren O, Berne C, Linet MS, Ekbom A, et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 1996; 88:1472–1477.
[105] Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002; 36:1206–1213.
[106] Hjalgrim H, Frisch M, Ekbom A, Kyvik KO, Melbye M, Green A. Cancer anddiabetes– a follow-up study of two population-based cohorts of diabetic patients. J Intern Med 1997; 241:471–475.
[107] Rapp K, Schroeder J, Klenk J, et al. Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria.Br J Cancer 2005;93:1062–1067.
[108] Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight,obesity and mortality from cancer in a prospective studied cohort of US adults. N Engl J Med 2003; 348:1625–1638.
[109] Samanic C, Gridley G, Chow WH, et al. Obesity and cancer riskamong white and black United States veterans. Cancer Causes Control 2004; 15:35–43.
[110] Lai MS, Hsieh MS, Chiu YH, et al. Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection. Hepatology 2006; 43:1295–1302.
[111] El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk ofchronic liver disease and hepatocellular carcinoma. Gasteroenterology 2004; 126:460–468.
[112] Davila JA, Morgan RO, Shaib Y, et al. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005; 54:533–539.
[113] CHI–LING CHEN,* HWAI–I YANG, WEI–SHIUNG YANG,et al. Metabolic Factors and Risk of Hepatocellular Carcinoma by Chronic Hepatitis B/C Infection: A Follow-up Study in Taiwan. GASTROENTEROLOGY 2008;135:111–121
[114] Hemminki K, Li X. Familial liver and gall bladder cancer: a nationwide epidemiological study from Sweden. Gut 2003; 52:592–596.
[115] McGlynn KA, Hunter K, Levoyer T et al. Susceptibility to aflatoxin B1-related primary hepatocellular carcinoma in mice and humans. Cancer Res 2003; 63: 4594–4601.
[116] Huang YS, Chern HD,Wu JC et al. Polymorphism of the N-acetyltransferase 2 gene, red meat intake, and the susceptibility of hepatocellular carcinoma. Am J Gastroenterol 2003; 98: 1417–1422.
[117] Yeh SH, Chang CF, Shau WYet al. Dominance of functional androgen receptor allele with longer CAG repeat in hepatitis B virus-related female hepatocarcinogenesis. Cancer Res 2002; 62: 4346–4351.
[118] Frisch M, Biggar RJ, Engels EA, Goedert JJ & AIDS-Cancer Match Registry Study Group. Association of cancer with AIDS-relatedimmunosuppression in adults. JAMA 2001; 285: 1736–1745.
[119] Darby SC, Ewart DW& Giangrande PL. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors’Organisation. Lancet 1997; 350: 1425–1431.
[120] Thio CL. Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment. Semin Liver Dis 2003; 23: 125–136.
[121] Elzouki AN, Eriksson S. Risk of hepatobiliary disease in adults with severe alpha 1-antitrypsin deficiency (PiZZ): is chronic viral hepatitis B or C an additional risk factor for cirrhosis and hepatocellular carcinoma? Eur J Gastroenterol Hepatol 1996; 8:989–994.
[122] Alexander J, Kowdley KV. HFE-associated hereditary hemochromatosis.Genet Med 2009; 11:307–313.
[123] Olynyk JK, Trinder D, Ramm GA, Britton RS, Bacon BR. Hereditary hemochromatosis in the post-HFE era. Hepatology 2008;48:991–1001.
[124] Elmberg M, Hultcrantz R, Ekbom A, Brandt L, Olsson S, Olsson R, et al. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 2003; 125:1733–1741.
[125] Seth AK, Badminton MN, Mirza D, Russell S, Elias E. Liver transplantation for porphyria: who, when, and how? Liver Transpl 2007; 13:1219–1227.
[126] Andant C, Puy H, Bogard C, Faivre J, Soule JC, Nordmann Y, et al.Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors. J Hepatol 2000;32:933–939.
[127] Aarsand AK, Boman H, Sandberg S. Familial and sporadic porphyriacutanea tarda: characterization and diagnostic strategies. Clin Chem2009; 55:795–803.
[128] Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol 2003;39:620–627.
[129] Hassan MM, Kaseb A, Li D, Patt YZ, Vauthey JN, Thomas MB, et al. Association between hypothyroidism and hepatocellular carcinoma: a case–control study in the United States. Hepatology 2009; 49:1563–1570.
[130] Liangpunsakul S, Chalasani N. Is hypothyroidism a risk factor for nonalcoholic steatohepatitis? J Clin Gastroenterol 2003; 37:340–343.
[131] Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, Tokushige K, et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol 2009; 44 (Suppl. 19):89–95.
[132] Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R, et al. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 2007; 11:119–132.
[133] Hill-Baskin AE, Markiewski MM, Buchner DA, Shao H, Desantis D, Hsiao G, et al. Diet-induced hepatocellular carcinoma in genetically-predisposed mice. Hum Mol Genet 2009; 18:2975–2988..
[134] Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533–543. CDC. Geographic Distribution of Chronic HBV Infection. Hepatitis B Slide Set (Internet) 2002.
[135] Hann HL, Kim C, London WT et al. Hepatitis B virus and primary hepatocellular carcinoma: family Studies in Korea. Int J Cancer 1982; 30: 47–51.
[136] Evans AA, Chen G, Ross EA et al. Eight-year follow-up of the 90,000-person Haimen City Cohort: I.Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol Biomarkers Prev 2002; 11: 369–376.
[137] CDC. Global progress toward universal childhood hepatitis B vaccination, 2003. MMWR 2003; 52: 868–869.
[138] Beasley RP. Hepatitis B virus, the major etiology of hepatocellular carcinoma. Cancer 1988; 61: 1942–1956.
[139] Man-Fung Yuen, Yasuhito Tanaka, Daniel Yee-Tak Fong,et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. Journal of Hepatology 50 (2009) 80–88
[140] Jaw-Ching Wu, Yi-Hsiang Huang, Gar-Yang Chau,et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. Journal of Hepatology 51 (2009) 890–897
[141] Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al.Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351:1521–1531.
[142] Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006; 44:1543–1554.
[143] Ahn JY, Jung EY, Kwun HJ,et al. Dual effects of hepatitis b virus X protein on the regulation of cell-cycle control depending on the status of cellular p53. J Gen Virol. 2002 Nov; 83(Pt11):2765-2772.
[144] Niederau C, Lange S, Heintges T et al. Prognosis of chronic hepatitis C:results of a large prospective cohort study. Hepatology 1998; 28: 1687–1695.
[145] Tagger A, Donato F, Ribero ML et al. Case–control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: the role of HCV genotypes and the synergism with hepatitis B virus and alcohol. Brescia HCC Study. Int J Cancer 1999; 81: 695–699.
[146] M. Levrero, Viral hepatitis and liver cancer: the case of hepatitis C, Oncogene 25 (27) (2006) 3834–3847.
[147] L. Golden-Mason, H.R. Rosen, Natural killer cells: primary target for hepatitis C virus immune evasion strategies? Liver Transplant. 12 (3) (2006) 363–372.
[148] H.J. Alter, L.B Seeff, Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome, Semin. Liver Dis. 20 (2000) 17–35. J.M. Pawlotsky, Diagnostic tests for hepatitis C, J. Hepatol. 31 (Suppl. 1) (1999) 71–79.
[149] D.G. Bowen, C.M. Walker, Adaptive immune responses in acute and chronic hepatitis C virus infection, Nature 436(7053) (2005) 946–952.
[150] R. Thimme, D. Oldach, K.M. Chang, C. Steiger, S.C. Ray, F.V.Chisari, Determinants of viral clearance and persistence during acute hepatitis C virus infection, J. Exp. Med. 194(10) (2001) 1395–1406.
[151] J.J. Chang, S.R. Lewin, Immunopathogenesis of hepatitis B virus infection, Immunol. Cell Biol. 85 (1) (2007) 16–23.
[152] M.P. Manns, J.G. McHutchison, S.C. Gordon, et al., Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: arandomised trial, Lancet 358 (2001) 958–965.
[153] A. Aghemo, M.G. Rumi, S. Monico, et al.The pattern of pegylated interferon alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype, Antivir. Ther. 14 (4) (2009) 577–584.
[154] P. Marotta, D. Hueppe, E. Zehnter, P. Kwo, I. Jacobson, Efficacy of chronic hepatitis C therapy in community-based trials, Clin. Gastroenterol. Hepatol. 7 (10) (2009) 1028–1036.
[155] Donato F, Ooffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer. 1998 Jan 30; 75(3):347-354.
[156] Befeler AS, DiBisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002; 122:1609–1619.
[157] Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology 2000; 31: 241–246.
[158] Bellentani S, Tiribelli C, Saccoccio G et al. Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study. Hepatology 1994; 20: 1442–1449.
[159] Bellentani S & Tiribelli C. The spectrum of liver disease in the general population: lesson from the Dionysos study. J Hepatol 2001; 35: 531–537.
[160] Velazquez RF, Rodriguez M, Navascues CA et al. Prospective analysis of risk factors for hepatocellularcarcinoma in patients with liver cirrhosis. Hepatology 2003; 37: 520–527.
[161] Friedman S, Schiano T. Cirrhosis and its sequelae. In: Goldman L, Ausiello D, eds. Cecil Textbook of Medicine. 22nd ed. Philadelphia, Pa.: Saunders, 2004:936-44.
[162] Crawford JM. Liver and biliary tract. In: Kumar V, Abbas AK, Fausto N, eds. Robbins and Cotran Pathologic Basis of Disease. 7th ed. Philadelphia, Pa.: Elsevier Saunders, 2005:877-938.
[163] Wu F,Chen WZ,Bai J,et a1.Tumor vessel destruction resulting from high intensity focused ultrasound in patients with solid malignancies[J].Ultra.sound Med Biol,2002,28(4):535-542.
[164] Gschwantler M, Vavrik J, Gebauer A, Kriwanek S, Schrutka-K?lbl C, Fleischer J, Madani B, Brownstone E, Tscholakoff D, Weiss W. Course of platelet counts in cirrhotic patients after implantation of a transjugular intrahepatic portosystemic shunt--a prospective, controlled study. J Hepatol 1999 Feb; 30(2):254-9.
[165] Ba?ares R, Nú?ez O, Escudero M, Fernández C, Vaquero J, Beceiro I, Echenagusía A, Clemente G, Santos L. Patients with cirrhosis and bare-Stent TIPS may have increased risk of hepatocellular carcinoma. Hepatology. 2005 Jul; 42(1):236.
[166] Yasuhiko Sugawara, MD, Junji Yamamoto, MD, Kazuaki Shimada, MD,et al. Splenectomy in Patients with Hepatocellular Carcinoma and Hypersplenism. J Am Coll Surg.2000 April; 190(4):446-450.
[167]王宇.门静脉高压症的外科治疗.中华外科杂志.2005,10;43(19):1234-1236.
[168]汪谦,夏穗生,姜汉英,等.脾脏及Tuftsin在肝硬化形成过程免疫调控机制探讨[J].中华医学杂志,1995,75(10):594-8.
[169] Fridkin M,Gottlieb P.Tuftsin,Thr-Lys-Pro-Arg[J].Mol cell Biochem,1981,41(1):73-77.
[170]王洪波,周宁新,李志伟,等.门脉高压患者脾切除术后免疫功能的改变及其与脾组织免疫细胞的关系.消化外科,2004,3(4):286-290.
[171]刘俊卯,端木浩,丁海.脾切除对肝炎后肝硬化门脉高压症免疫功能的影响.中华医学丛刊,2003,3:13-14.
[172]吴仕和,仇登波,黄韬.门脉高压症患者脾脏免疫学研究[ J ] .湖南医学, 2001 , 18 (1) :124.
[173]汪谦,程庆君,郭全鹏.门脉高压巨脾原位保留和异位移植组织变化与功能比较[J ] .蚌埠医学院学报, 1991 , 16 (1) :55256.
[174]吴厚慧,徐鹿平,刘凤强,等.肝硬化巨脾切除对免疫功能的影响.肝胆胰脾外科杂志.2000,12(2):18-20.
[175]曹志新,陈孝平,吴在德.肝癌合并肝硬化患者脾脏Thl/Th2细胞因子免疫状态的研究.中华实验外科杂志.2001, 11(18): 518- 519.
[176]王新,陈岳祥,许才绂,赵国宁,黄裕新,王庆莉.肿瘤坏死因子α与人肝纤维化关系的研究.华人消化杂志,1998,6(2):106—108.
[177] Murata K, Shiraki K, Sugimoto K, Takase K, Nakano T, Furusaka A, Tameda Y.Splenectomy enhances liver regeneration through tumor necrosis factor (TNF)-alpha following dimethylnitrosamine-induced cirrhotic rat model.Hepatogastroenterology. 2001 Jul-Aug;48(40):1022-7.
[178]彭建平,叶德存,顾霞,等.脾切除影响肝硬变的机理探讨.中国普外基础与临床杂志.2003,10(3):222-225.
[179] Cho JJ, Hocher B, Herbst H, Jia JD, Ruehl M, Hahn EG, Riecken EO, Schuppan D.An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis. Gastroenterology. 2000 Jun;118(6):1169-78.
[180] Nagasue N, Dhar DK, Yamanoi A, Emi Y, Udagawa J, Yamamoto A, Tachibana M, Kubota H, Kohno H, Harada T.Production and release of endothelin-1 from the gut and spleen in portal hypertension due to cirrhosis. Hepatology. 2000 May; 31(5):1107-1114.
[181]陈黎明,王陆军。张鸿飞,程云,辛绍杰,陈菊梅,张晓峰.肝硬化患者脾切除术前后血清血小板衍生生长因子—AB检测分析.中华肝脏病杂志,2003,11:748.
[182]陆新良,朱志鑫,蔡建庭,唐训球,钱可大,周君富.脾切除有助于纠正肝硬化患者氧化和抗氧化的失衡.临床肝胆病杂志,2002,18(5):313-315.
[183] BrittonRS,Bacon BR.Role of free radicals in liver diseases and hepatic fibrosis[J].Hepatogastroenterology,1994,41(4):343—8.
[184] Oh JW, Ahn SM, Kim KS, Choi JS, Lee WJ, Kim BR. The role of splenectomy in patients with hepatocellular carcinoma and secondary hypersplenism.Yonsei Med J. 2003 Dec 30; 44(6):1053-8。
[185]汪谦,彭慧,黄洁夫.门静脉高压病理脾切除疗效分析与远期随访.中华肝胆外科杂志,2000,6:21-23.
[186] Sekiguchi T, Nagamine T, Takagi H, Mori M. Reduction of virus burden-induced splenectomy in patients with liver cirrhosis related to hepatitis C virus infection. World J Gastroenterol 2006;12(13):2089–94. 7.
[187] Magdy M.A. Elsebae*, Nadia B. Abu-Zekri. A study of the effect of splenectomy on hepatic functional reserve and structural damage in patients with chronic hepatitis C virus infection by non-invasive serum markers. A prospective study. International Journal of Surgery 6 (2008) 362–366.
[188]刘支援,何兴舟.近十年来病例对照研究方法的应用.国外医学卫生学分册,1987,2:88—91.
[189]陈延,詹思延,李立明.病例对照研究发展历史.中华流行病学杂志.2004,3;25(3):273-275.
[190] Rosenbaum PR, Rubin DB. The central role of the propensity score inobservational studies for causal effects. Biometrika 1983; 70:41–55.
[191] Cochran WG. The effectiveness of adjustment by Subclassification in removing bias in observational studies. Biometrics , 1968 , 24∶295-313.
[192] Katherine HH ,Thomas AL. Propensity score modeling strategies for the causal analysis of observational data. Biostatistics , 2002 , 2∶179-193.
[193]汪涛,山口拓洋,大桥靖雄,等.倾向指数方法的蒙特卡罗研究.中华流行病学杂志.2005,6;26(6):458-462.
[194] Velázquez RF, Rodríguez M, Navascués CA, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis[J]. Hepatology, 2003, 37(3): 520-527.
[195]韩国庆,秦成勇,任万华,等.γ-谷氨酰转移酶mRNA亚型对肝细胞癌变的监测[J].中华内科杂志, 2002,41(3):160-162.
[196] Takayashiki T, Yoshidome H, Kimura F, et al. Increased expression of toll-like receptor 4 enhances endotoxin-induced hepatic failure in partially hepatectomized mice[J]. J Hepatol , 2004, 41(4): 621-628.
[197] Takashi Kumada*, Hidenori Toyoda, Seiki Kiriyama, et al. Incidence of hepatocellular carcinoma in hepatitis C carriers with normal alanine aminotransferase levels[J]. Journal of Hepatology, 2009, 50: 729–735.
[198] Magdy M.A. Elsebae*, Nadia B. Abu-Zekri. A study of the effect of splenectomy on hepatic functional reserve and structural damage in patients with chronic hepatitis C virus infection by non-invasive serum markers. A prospective study [J]. International Journal of Surgery, 2008, 16: 362–366.
[199] J.L. Rodri′guez-Di′az*, V. Rosas-Camargo*, O. Vega-Vegaz , et al. Clinical and Pathological Factors Associat-ed the Development of Hepatocellular Carcinoma in Patients with Hepatitis Virus-relatedCirrhosis: A long-term Follow-up Study[J]. Clinical Oncology , 2007,19: 197-203.
[200] Ve la′zquez R, Rodr?′guez M, Navascue′s CA, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis[J]. Hepatology, 2003, 37: 520-527.